Project Grant R01AG094488
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) provides $703,644 to the Icahn School of Medicine at Mount Sinai to investigate the drivers of accelerated aging in people living with HIV (PWH). The research aims to study the effects of HIV and antiretroviral therapy on epigenetic aging and clonal hematopoiesis, as well as examine the role of socio-behavioral factors and genetic predisposition in...
- This $527,129 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to identify biomarkers and develop novel strategies to prevent or treat inflammation-associated comorbidities in people living with HIV on antiretroviral therapy. The award recipient, Northwestern University, will conduct research to examine how glycomic alterations in circulating IgGs may contribute to HIV-associated inflammation and identify these alterations as potential...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), supports research to investigate the relationship between HIV infection, aging, and cognitive decline. The $629,712 award to SRI International aims to leverage magnetic resonance imaging (MRI) and biomarker analysis to better understand how the brain's waste clearance system, known as the glymphatic system, may contribute to heightened risk of cognitive impairment in aging...
- This federal Project Grant award of $2,981,544.00, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a study to assess the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with treated HIV infection. The study will leverage data from a prior clinical trial of the CMV-specific antiviral drug letermovir and a case-cohort study of over 1,900 ART-suppressed people with HIV to...
- The National Institute on Aging (NIA), through its Aging Research program (CFDA 93.866), has awarded a $534,644.00 Project Grant to Temple University - Of The Commonwealth System Of Higher Education. The grant aims to characterize how the HIV-1 virus decreases neuronal clearance, leading to the progression of HIV-associated neurocognitive disorders like motor dysfunction. Key research activities include determining the post-translational regulation of the SNAPIN protein and its impact on...
- This Project Grant award, totaling $428,493, was provided by the U.S. Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The grant was awarded to The Johns Hopkins University on September 5, 2025 to support a research project titled "Characterizing and Predicting Comorbidity Cascade Among Men and Women With and Without HIV by Harnessing Data from MWCCS and Electronic Medical Records." The key...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,016,951 to The University of Texas MD Anderson Cancer Center to conduct research on reversing the immune system changes that lead to the establishment of the HIV reservoir during antiretroviral therapy (ART) initiation. The goal is to use TGF-beta blockade, combined with broadly neutralizing...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This $1,015,194 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Prevention of Disease, Disability, and Death by Infectious Diseases program (CFDA 93.084) supports research at the University of Colorado-Denver to understand integrative care and support pathways to healthy aging for adults aging with HIV. The 3-year project, which runs from September 30, 2025 to September 29, 2028, aims to develop innovative strategies for addressing the complex...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
THE NEXUS OF TRAINED IMMUNITY AND STABLE IMMUNE COMPLEXES: IMPLICATIONS FOR AGING-RELATED CONDITIONS IN PLWH - PROJECT SUMMARY APPROXIMATELY 38.4 MILLION PEOPLE ARE LIVING WITH HIV GLOBALLY, AND THERE ARE STILL NEW INFECTIONS DAILY. PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY ARE AGING AT A FASTER RATE THAN THEIR PEERS. THIS IS LIKELY DRIVEN BY THE HIV RESERVOIR THAT PERSISTS EVEN IN AVIREMIC PATIENTS. THE HIV RESERVOIR AND OTHER CO-INFECTIONS, SUCH AS CYTOMEGALOVIRUS (CMV), PROMOTE CHRONIC INFLAMMATION, WHICH FURTHER CONTRIBUTES TO ACCELERATED AGING. OUR OVERARCHING HYPOTHESIS IS THAT CHRONIC INFLAMMATION ACCELERATES AGING-RELATED DISEASES SUCH AS DIABETES, CARDIOVASCULAR DISEASE, AND CANCER IN PEOPLE LIVING WITH HIV, EVEN IN THE ABSENCE OF DETECTABLE VIRAL LOAD. IN PREVIOUS STUDIES, OUR GROUP DEMONSTRATED THAT PEOPLE LIVING WITH HIV EXHIBIT A SIGNIFICANT INCREASE IN CMV- SPECIFIC CD4+ T CELLS, A PHENOMENON DESCRIBED AS 'INFLATION.' THIS INFLATION IS UNIQUE TO HIV, AS SIMILAR INCREASES HAVE NOT BEEN OBSERVED IN STUDIES OF IMMUNE SUPPRESSION IN TRANSPLANT PATIENTS, SUGGESTING AN INTERACTION BETWEEN HIV AND CMV. BEYOND THIS, PEOPLE LIVING WITH HIV WITH METABOLIC DISEASE HAVE INCREASED PROPORTIONS OF CIRCULATING IMMUNE COMPLEXES (CD3+ T CELL CD14+ MONOCYTES). TRADITIONALLY, THESE COMPLEXES HAVE BEEN DISMISSED AS ARTIFACTS. HOWEVER, STUDIES SUGGEST THAT THESE ARE FUNCTIONAL COMPLEXES. IN PEOPLE WITH HIV, THESE COMPLEXES ARE ACTIVATED, INVERSELY CORRELATED WITH CD4+ REGULATORY T CELLS AND PLASMA INTERLEUKIN (IL)-10 LEVELS AND CONTAIN REPLICATING HIV. THESE FINDINGS HIGHLIGHT THE ROLE OF THESE COMPLEXES IN HIV AND METABOLIC DISEASES. GIVEN THEIR FUNCTIONAL NATURE, CD3+ T CELL CD14+ MONOCYTE COMPLEXES PROVIDE A UNIQUE OPPORTUNITY TO DEFINE THE ANTIGEN DRIVERS IN DIABETES, CARDIOVASCULAR DISEASE, AND AGING TO DEVELOP TARGETED IMMUNE INTERVENTIONS WITH FEWER ADVERSE EFFECTS. THIS PROPOSAL WILL LEVERAGE THE CENTER FOR AIDS RESEARCH NETWORK OF INTEGRATED CLINICAL SYSTEMS (CNICS), A LONGITUDINAL COHORT OF PATIENTS WITH ADJUDICATED OUTCOMES ACROSS MULTIPLE SITES, TO STUDY THE IMMUNE COMPLEXES OVER TIME. WE PROPOSE THREE AIMS. IN THE FIRST AIM, WE WILL INVESTIGATE WHETHER IMMUNE COMPLEXES ARE ELEVATED IN PEOPLE LIVING WITH HIV WHO ALSO HAVE CARDIOVASCULAR DISEASE OR CANCER. THIS APPROACH WILL ENABLE US TO DETERMINE WHETHER THE IMMUNE COMPLEXES IN THESE INDIVIDUALS DIFFER FUNCTIONALLY FROM THOSE FOUND IN PEOPLE LIVING WITH HIV AND DIABETES. IN THE SECOND AIM, WE WILL TEST THE HYPOTHESIS THAT BOTH HOST-DERIVED FACTORS, SUCH AS MAJOR HISTOCOMPATIBILITY COMPLEXES, AND NON- HOST-DERIVED FACTORS, INCLUDING SMOKING, METABOLITES, AND LIPIDS, PROMOTE THE FORMATION AND PERSISTENCE OF IMMUNE COMPLEXES. FINALLY, THE THIRD AIM WILL EXAMINE WHETHER CD3+ T CELLS WITHIN THESE COMPLEXES INDUCE EPIGENETIC CHANGES IN CD14+ MONOCYTES, LEADING TO PATHOGENIC TRAINED IMMUNITY. WE SEEK TO IDENTIFY MECHANISMS DRIVING AGING IN PEOPLE LIVING WITH HIV, ULTIMATELY PAVING THE WAY FOR TARGETED THERAPIES THAT COULD SLOW DOWN AGING AND REDUCE COMORBIDITIES IN THIS POPULATION. OUR FINDINGS WILL INFORM THE DEVELOPMENT OF TARGETED ANTI-INFLAMMATORY THERAPIES, POTENTIALLY TRANSFORMING THE MANAGEMENT OF AGING-RELATED COMORBIDITIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $32.6k | 8/20/25 |